Ovarian cancer || Public Health Genomics Knowledge Base (v1.2) || Ovarian cancer

Public Health Genomics Knowledge Base (v1.2)



Last Updated: Nov 01, 2016

• Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
  Dimitrova Desislava, et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 9 (9) 12329-12337
• VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.
  Camerin Gabriela Ribeiro, et al. Future oncology (London, England) 2016 10
• Whole-exome sequencing of Finnish hereditary breast cancer families.
  Määttä Kirsi, et al. European journal of human genetics : EJHG 2016 10
• http://www.mdedge.com/jcso/article/110048/gynecologic-cancer/hereditary-breast-and-ovarian-cancer-risk-assessment-minority
  Disease: Breast Cancer|Ovarian Cancer; Type: Data|Program; State: Georgia
• Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
  Disease: Ovarian Cancer|Breast Cancer; Type: Data|Program; State: Georgia
• The Associations of Genetic Variants in E-cadherin Gene With Clinical Outcome of Epithelial Ovarian Cancer.
  Juan Wang, et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2016 11 (9) 1601-1607
• Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer.
  Kast Karin, et al. Archives of gynecology and obstetrics 2016 11 (6) 1299-1303
• Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
  Zaaijer Leendert H, et al. British journal of cancer 2016 10
• Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
  Alemar Bárbara, et al. Cancer genetics 2016 9 (9) 417-422
• Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.
  Dirix Luc, et al. Clinical therapeutics 2016 10
• A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
  Isakoff Steven J, et al. Future oncology (London, England) 2016 10
• Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
  Fernandes Gabriela C, et al. Oncotarget 2016 10
• HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.
  Ross-Adams Helen, et al. Oncotarget 2016 10
• Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
  Dagan E, et al. European journal of cancer care 2016 10
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
  Mirza Mansoor R, et al. The New England journal of medicine 2016 10

• CDC Information (10)
• CDC-Authored Pub (7)

• Human (57)
• Pathogen (0)

• Human (1528)
• Pathogen (0)

• Human (241)
• Pathogen (0)

• Guidelines (11)
• Tier Table (4)
• Synthesis (15)

• Huamn (107)
• Pathogen (0)

Relevant Resources

• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB